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ABSTRACT 
The synthesis of bile acids is the major biological mechanism for cholesterol removal 
in the human body. Strict regulation of both cholesterol and bile acid levels is 
necessary to maintain a healthy balance and to prevent health problems. Bile acids are 
natural ligands for famesoid x receptor (FXR), a nuclear receptor that controls gene 
expression for multiple proteins involved in maintenance of bile acid homeostasis. 
Many endogenous and exogenous chemical ligands have been found to activate FXR; 
chenodeoxycholic acid (CDCA) is the most well characterized endogenous ligand. 
This study identifies a synthetic indole-acetamide, FGIN-1-27, as a new FXR agonist. 
FGIN-1-27 is already a known ligand of the translocator protein 18 kDa (TSPO), a 
mitochondrial cholesterol transporter. 
FXR regulates target gene transcription through binding to special inverted repeat-I 
(IR-1) consensus DNA elements. Ligand binding to FXR was measured by inserting 
an IR-1 sequence upstream of a firefly luciferase detector gene that increased 
transcription of luciferase pr:oportional to ligand binding in a human hepatoma cell 
line (HuH-7). Results show that FGIN-1-27 is a partial agonist of FXR that activates 
FXR alone at 10 µM, but decreases activation from CDCA at 100 µM when cotreated. 
Two other well-known ligands of TSPO, FGIN-1-43 and PKl 1195 were investigated 
also for their effects on FXR mediated transcription. Both compounds acted as 
antagonists, decreasing the activity of CDCA (100 µM) while showing no activation 
of FXR alone at 1 O µM treatment. 
Agonist ligand binding to FXR increases the expression of the target gene, bile salt 
export pump (BSEP), and another nuclear receptor, small heterodimer partner (SHP). 
Through real time RT-PCR DNA amplification of both genes, we found FGIN-1-27 
treatment in HuH-7 cells and primary human hepatocytes increased both BSEP and 
SHP gene expression. Additionally, expression of cholesterol 7a-hydroxylase 
(CYP7 Al), an enzyme involved in bile acid synthesis, is negatively regulated by FXR; 
we show that FGIN-1-27 decreased the expression ofCYP7Al. 
In addition to in vitro studies, we investigated in silica molecular modeling of the 
binding of these TSPO ligands to FXR and demonstrated that these synthetic 
compounds fit into the ligand-binding pocket of FXR with favorable energy 
measurements. We identified key amino acids involved in agonist ligand binding in 
silica, and through mutation assays we confirmed that H447 is the major amino acid 
responsible for FXR interaction with an agonist ligand. 
Taken together, FGIN-1-27 binding to and modulating two of the proteins involved in 
bile acid synthesis indicates there is overlap in the role of TSPO and FXR. FGIN-1-27 
and related indole-acetamides may be potential therapeutic drugs beneficial to 
populations with enzyme deficiencies that cause high cholesterol levels. Further 
investigation of the role of mitochondria in bile acid synthesis will lead to a better 
understanding of the regulation of cholesterol and bile acid homeostasis. 
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1. INTRODUCTION 
1.1 Cholesterol and bile acid homeostasis 
Bile acids are natural emulsifiers of dietary lipids, cholesterol, and fat-soluble vitamins 
(l). They are secreted into the small intestine and ultimately control the amount of 
cholesterol that is absorbed from the diet. Accumulation of excess cholesterol in 
circulation, due to deficiencies in enzymes of cholesterol catabolism, poor health and 
diet, and other risk factors, can lead to atherosclerosis and coronary heart disease (2,3). 
If the excretion of bile acids is hindered, the liver will accumulate these cytotoxic 
substances that are normally effluxed to the gall bladder and eventually to the 
duodenum, leading to cholestasis ( 4). The synthesis of bile acids must be tightly 
regulated to maintain homeostasis between cholesterol and bile acid concentrations. In 
adult human liver, approximately 500 mg of cholesterol is converted into bile acids 
each day through multiple pathways involving 16 different enzymes (reviewed by 
Russell (1)). About 95% of bile acids are re-circulated throughout the body before 
returning to the liver, while the other 5% are removed from the body through fecal 
matter. The biosynthesis of bile acids makes up about 90% of all cholesterol 
catabolism, with the remaining 10% going to steroid hormone biosynthesis (1,5,6). 
Bile acid synthesis occurs through two main pathways, the classic/neutral and the 
alternative/acidic, each of which is initiated by a cytochrome P450 enzyme (CYP)1 
(extensively reviewed in (1,5,7-9)). CYP enzymes are a special gene superfamily 
I 
See complete list of abbreviations (section 6) page 51. 
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responsible for the metabolism of multiple xenobiotic and endogenous compounds 
(1O,11 ). Of the 57 human CYP genes, only seven take part in bile acid biosynthesis 
(?). Six of the bile acid synthesis CYP enzymes are present on endoplasmic reticulum 
of eukaryotic cells, the seventh being found only inside the inner mitochondrial 
membrane (12). Nuclear receptors often regulate transcription of cytochrome P450 
genes through negative feedback from accumulation of a substrate, such as bile acids 
and oxysterols (13,14) . 
Most bile acids (~90%) are produced in the liver through the classic pathway, initiated 
by the rate-limiting cholesterol ?a-hydroxy lase (CYP7 Al) microsomal enzyme that 
converts cholesterol to 7a-hydroxycholesterol (1,15). The remaining 10% of bile acids 
are synthesized through the alternative pathway initiated by mitochondrial sterol 27-
hydroxylase (CYP27Al) in extrahepatic tissues (16,17) or cholesterol 24-a 
hydroxylase (CYP46Al) in the brain (18). The alternative pathway forms oxysterols 
that must be further converted into bile acids through ?a-hydroxylation (19). 
Cholesterol homeostasis must be maintained i~ the brain as in other tissues, but 
cholesterol cannot readily cross the blood brain barrier. To overcome this problem, 
CYP46Al produces 24S-hydroxycholesterol, an oxysterol that can cross the blood 
brain barrier, and be further converted into bile acids in the liver via the oxysterol 7a-
hydroxylase (CYP39Al) (20). The CYP27Al-initiated pathway forms predominantly 
27-hydroxycholesterol, which is 7a-hydroxylated by CYP7Bl (21). CYP27Al is 
involved also in both pathways further downstream in ring modifications to oxidize 
and cleave the sterol side chain (1, 19). The alternative pathway produces solely 
3 
chenodeoxycholic acid (CDCA), while the classic pathway produces both CDCA and 
cholic acid (CA) (8). The relative abundance of CA versus CDCA is ultimately 
regulated by sterol 12a-hydroxylase (CYP8Bl) (7). Figure 1 illustrates both pathways 
of bile acid synthesis in a condensed version showing only intermediates produced 
directly by CYP enzymes. 
Since strict enzymatic control is required to prevent bile acid or cholesterol 
accumulation, mutations of CYP enzyme genes can have potentially drastic 
consequences. CYP7Al and CYP27Al are two main CYP enzyme genes with 
mutations most often associated with cholesterol metabolic diseases and conditions. A 
homozygous mutation in CYP7A1 is associated with hypercholesterolemia, a 
condition of high total cholesterol and low-density lipoprotein cholesterol (LDL-C) 
concentrations accumulating in plasma, and accumulation of cholesterol in the liver 
with limited bile acid synthesis or excretion (22-24). Studies have shown that 40-60% 
of the Caucasian North American population are carriers of an A to C substitution 
polymorphism in the CYP7Al promoter region producing a high LDL-C phenotype 
with a recessive CYP7 Al -/- mutation that is more prevalent in men (23,25,26). Some 
individuals with this substitution have been shown to be resistant to cholesterol-
lowering 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors 
and experienced premature gallstones from bile acid accumulation (23). It is 
hypothesized that the inhibition of cholesterol synthesis by HMG-CoA reductase 
inhibitors would not significantly decrease total cytosolic cholesterol concentrations, 
therefore the increase in LDL receptor expression normally resulting from inhibition 
4 
of cholesterol synthesis, thus decreasing LDL-C in blood, would be limiting with little 
effect on lowering LDL-C concentrations (23). 
Lower than normal CA concentration is often an indicator of CYP7 Al deficiency as a 
result of the classic pathway being absent with compensation by the acidic pathway 
that produces only CDCA (22); typically the ratio of CA to CDCA is 2:1 (7,22). In the 
event of this compensation, CYP27Al activity doubles preventing complete 
deficiency of CYP7 Al from being lethal (23). Components of the acidic pathway can 
also be affected by mutations. Mutations that decrease CYP27 Al expression or 
activity lead to irregular cholesterol catabolism, and are involved in cerebrotendinous 
xanthomatosis (CTX), an inherited syndrome of neurological problems and premature 
atherosclerosis (27,28). The 40 known gene mutations that cause CTX are implicated 
in the build-up of cholestanol (a sterol cholesterol derivative) in myelin sheaths in the 
nervous system. If the disease is discovered early enough it is often treatable with oral 
bile acid therapy (1 ,5). 
1.2. Role of trans locator protein (18 kDa) 
The acidic pathway is limited not by the initial enzyme CYP27A1 itself, but by the 
delivery of cholesterol to CYP27 Al in the mitochondria (29). The transport of 
cholesterol into the mitochondria occurs through the translocator protein 18 kDa 
(TSPO), which is located predominantly on the outer mitochondrial membrane 
(OMM) (30,31) in cells of the adrenal glands, lung, heart, liver, and multiple other 
tissues (32). TSPO possesses five membrane-spanning domains that can form 
5 
multimeric protein polymers able to bind endogenous ligands that facilitate cholesterol 
binding (31,33). The polymer formation is facilitated by reactive oxygen species most 
likely produced from the CYP enzyme activity inside the mitochondria (31 ). TSPO, 
however, does not act alone and requires the assistance of steroidogenic acute 
regulatory (STAR) protein (34) (Fig. 2). Through a complex pathway, cholesterol 
binds to STAR in the cytoplasm for transport to the mitochondria (35), then STAR 
binds to the OMM (36), where cholesterol can be transported to TSPO and mobilized 
across the outer to the inner mitochondrial membrane. Binding of ligands to TSPO, 
including the endogenous ligand, diazepam-binding inhibitor, allows cholesterol to be 
transported into the mitochondrial, (37-39). Both endogenous and exogenous ligands 
increase 27-hydroxycholesterol production, identifying the availability of cholesterol 
to CYP27Al as the rate-limiting step in the alternative pathway (40). 
1.3 Role of nuclear receptors 
In high concentrations, bile acids can be toxic, so the potential toxicity is regulated by 
negative feedback ( 41 ). Bile acid synthesis is reduced in the presence of high bile acid 
concentrations, and conversely, low concentrations result in bile acid synthesis 
activation to increase the bile acid pool (1). Bile acid feedback is regulated by nuclear 
receptors that directly control target genes by activating or repressing transcriptional 
activities. Typically, nuclear receptors have a DNA binding domain that recognizes 
specific DNA sequences (hormone response elements) through a zinc finger region, 
and a ligand-binding domain (LBD). The response elements are comprised of half-
sites at least 6 base pairs long (typically AGGTCA) (42,43). Nuclear receptors bind to 
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e elements as either a homo/heterodimer to sequences of direct (DR) (-7-7), res pons 
everted (ER) (~-7) or inverted (IR) (-7~) repeats spaced by 1-5 nucleotides, or as a 
monomer, binding only to a half site ( 44 ). Helix 12 of the LBD is a ligand dependent 
activation function-2 (AF-2) domain, which upon agonist ligand binding to the 
receptor will recruit a coactivator protein with acetyltransferase activity ( 43). 
Acetylation of residues on histone proteins causes relaxation of the chromatin 
structure so the transcriptional machinery can gain access to the DNA to increase gene 
transcription ( 45). 
The endogenous bile acid receptor, famesoid x receptor (FXR; NR1H4), a member of 
the nuclear receptor superfamily ( 46), is a good potential target for pharmacological 
therapy to regulate bile acid concentrations, and thus cholesterol concentrations. FXR 
forms an exclusive heterodimer with retinoid x receptor a (RXRa; NR2Bl) (47) (the 
heterodimer formation occurs independent of ligand and DNA binding, but it is 
necessary for FXR receptiveness to bile acid ligand binding (47,48)). Multiple studies 
show that the primary and secondary bile acids: CDCA, lithocholic acid, and 
deoxycholic acid, are endogenous ligands of FXR, which in tum regulate bile acid 
homeostasis through transcriptional effects on specific genes ( 49-51 ). The most potent 
endogenous ligand of FXR is CDCA (50,51) and CDCA binding to FXR recruits the 
steroid receptor coactivator-1 (SRC-1) to the LBD ( 46,50,51 ). Along with bile acids, 
potent exogenous ligands of FXR have been made, including the potent synthetic 
agonists GW4064 (52), fexaramine (53) AGN29 and AGN31 (54). Additionally, 
7 
guggulsterone, a compound isolated from the guggul tree traditionally used m 
Ayurvedic medicine, is a natural antagonist of FXR (55). 
Agonist ligands of FXR play a major role in feedback regulation of bile acid synthesis. 
FXR can indirectly repress CYP7 Al expression through an FXR-activated small 
heterodimer partner (SHP; NROB2) pathway (56). FXR binds to an IR-1 repeat on the 
promoter region of SHP increasing SHP transcription and expression (57). SHP then 
interacts with other nuclear receptors, either liver receptor homolog-1 (LRH-1; 
NR5A2) (58,59) or hepatic nuclear factor-4 (HNF4; NR2Al) (60), by competing for 
coactivators, recruiting corepressors, or through its own intrinsic corepressor function 
( 61 ). LRH-1 binds as a monomer to the promoter region of CYP7A1 gene ( 5 ' -
TCAAGGCCA-3') (56,62), while HNF4 binds as a homodimer to a DR-1 response 
element (5'-TGGACT T AGTTCA-3') (63). FXR is known also to increase bile acid 
efflux from the liver. FXR binds to an IR-1 repeat (5'-GGGACA T TGATCCT-3') on 
the promoter region of the gene for bile salt export pump (BSEP), an ATP-mediated 
receptor on the bile canaliculi, increasing its expression (64). The liver specific BSEP 
is the principal bile acid efflux transporter that pumps bile acids against a strong 
concentration gradient out of the liver; precise control of this receptor is essential for 
maintenance of bile acid homeostasis (65,66). 
In most cases, agonist activation of FXR should lower cholesterol up-take by 
diminishing the liver bile acid pool through increased efflux and through inhibition of 
CYP7Al activity, thereby inhibiting cholesterol absorption in the intestine (67). 
8 
r thl. s is not always the case since FXR agonists would show little effect in Howeve, 
people lacking functional CYP7Al enzymes. Also, CYP27Al is not a rate-limiting 
me so bile acids and their intermediates have less effect on this pathway in enzy , 
comparison to CYP7Al; agonist effects of FXR through bile acids typically do not 
regulate transcriptional activity of CYP27A1 directly ( 68,69). Individuals with poor 
synthesis via the classic pathway, therefore, may therapeutically benefit from relevant 
and useful targets of TSPO as a modulator of the alternative pathway. 
1.4. TSPO and FXR interplay 
It is possible that many of the known ligands of TSPO could additionally regulate the 
cholesterol turnover rate by acting upon other receptors. Since both mitochondrial and 
nuclear receptor signaling pathways are involved in maintenance of bile acid 
homeostasis, this study was designed to investigate the interplay between TSPO and 
FXR by demonstrating TSPO ligands modulate FXR activity also. PKl 1195, one of 
the most well known and widely used ligands of TSPO, is known to increase the 
cholesterol binding rate to the protein (31,70,71). Similarly, a series of 2-aryl-3-
indoleacetamides (named FGIN-1), designed by Romeo et al. (72), selectively bind to 
TSPO (73,74). The aim of this study was to investigate binding of PKl 1195 and 
FGIN-1 compounds to modulate FXR target genes and to provide evidence of binding 
pocket interactions with these compounds. We have found that FGIN-1-27 is a partial 
agonist of FXR that activates downstream transcription of FXR target genes, as 
demonstrated in both optimized luciferase assays and measurements of endogenous 
gene expression in liver cells. We show that FGIN-1-43 is a selective antagonist, able 
9 
to block FXR agonist activation of FGIN-1-27 but is less inhibitory of CDCA 
activation of FXR. PKl 1195, on the other hand, is a non-selective FXR antagonist. 
Through in vitro transcriptional and mRNA expression studies and in silica molecular 
modeling studies we show that each of these compounds binds directly to the FXR 
LBD. Activation of both TSPO and FXR with one compound is favorable for dual 
maintenance of bile acid and cholesterol homeostasis. 
10 
2. EXPERIMENTAL PROCEDURES 
2. l. Chemicals and biochemicals 
COCA (sodium salt) was purchased from Sigma-Aldrich® (St. Louis, MO). FGIN-1-
27, FGIN-1-43, and PK11195 were purchased from Tocris Bioscience (Ellisville, 
MO). Dimethyl sulfoxide (DMSO), used as a negative control with all treatments, was 
purchased from Fisher Scientific (Pittsburgh, PA). The y-aminobutyric acid (GABA)-
ergic ligand library (version 3.6, lot# N1205) was purchased from Biomol (now Enzo 
Life Sciences, Plymouth Meeting, PA). Cell culture media and additives were from 
Invitrogen/GIBCO Corp. (Carlsbad, CA) or Lonza (Hopkington, MA). 
2.2. Plasmid constructs 
Consensus FXR response element (FXRE) (75) contained four copies of the IR-1 
sequence (underlined) 5' -ACAAGAGGTCATTGACCTTGTCC-3'. Forward and 
reverse oligonucleotides of the IR-1 sequence were annealed and blunt-end ligated 
into the Sma I site of luciferase vector pTK-Luc. To make pTK-Luc, pGL3-Basic 
vector (Promega, Madison, WI) was cut with Bglll and blunted with T4 polymerase. A 
DNA fragment ( 165 bp) containing the core thymidine kinase (TK) promoter was cut 
from vector pBLCA T2, blunted with T4 polymerase and ligated into pGL3 vector 
maintaining the original multiple cloning site. Original pTK-Luc and FXRE-TK-Luc 
cloning was performed in the laboratory of Dr. Curtis Omiecinski (The Pennsylvania 
State University, State College, PA). Expression plasmids for FXR were produced in 
pcDNA3. l vector (Invitrogen/GIBCO), p3XFLAG vector (Sigma Aldrich) and pM 
11 
(BD Bioscience San Jose, CA). Human liver cDNA was subjected to PCR vector ' 
amplification of FXR gene us mg gene-specific pnmers (FP: 5'-
CGCGGATCCTAGCCGCCATGGGATCAAAAA TGAATCTC-3' and RP: 5 ' -
GCTCTAGATCACTGCACGTCCCAGATTTCA-3'); primers were designed to 
amplify cDNA coding for the full 472 amino acid FXR sequence (NM_005123). FXR 
PCR product and vector were separately digested with BamHI and Xbal before being 
combined for ligation. For a mammalian two-hybrid assay, the reporter vector, pFR-
Luc, containing five copies of an upstream activation sequence (UAS) that binds to 
GAL4 protein (76), was cloned upstream of the firefly luciferase gene. pVP16-FXR 
contained the full-length FXR cloned downstream of, and fused to, VP16 activation 
function. GAL4-containing plasmid pM-SRC-1 was made by PCR amplification of 
SRC-1 sequence coding for amino acids 570-780 (contains one of the receptor 
interacting domains (RID)) using the following primers, based on gene accession 
number NM 003734: FP: 5'-GATCGAATTCCCTAGCAGATTAAATATACAA 
CCAG-3' and RP: 5 '-GATCTCTAGATCACATCTGTTCTTTCTTTTCCACTT-3 '. 
PCR-amplified product was digested with EcoRI and Xbal for cloning into pM. 
2.3. Cell culture 
HuH-7 cells (JTC-39), a differentiated hepatoma cell line, were originally from 
Okayama University JCRB Cell Bank and kindly provided by Dr. Ruitang Deng, 
University of Rhode Island, Kingston, RI. COS-I cell line (African Green Monkey 
kidney cells transformed with Simian Virus 40) and ZR-7 5 (breast cancer cell line) 
were obtained from American Type Culture Collection (ATCC, Manassas, VA). HuH-
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7 and COS-1 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
I mented with 5% fetal bovine serum (FBS), 1 % penicillin/streptomycin, 1 % supp e 
Glutamax, and 0.15% sodium bicarbonate, 1% sodium pyruvate, 10 mM HEPES 
b fli and 1 % non-essential amino acids (Invitrogen/GIBCO). ZR-75-1 cells were u er, 
maintained in RPM! 1640 medium with 10% FBS and the same concentrations of 
additives as for DMEM. Additionally, primary human hepatocytes were obtained from 
an NIH-funded liver tissue cell distribution system (LTCDS) through Dr. Steven 
Strom at the University of Pittsburgh (Pittsburgh, PA). The human hepatocytes were 
seeded onto collagen type IA-coated culture plates and maintained with Williams' 
Media E medium supplemented with isulin-transferrin-selenium (ITS+) solution, 100 
nM dexamethasone, linoleic-bovine serum albumin conjugate, penicillin/streptomycin 
and L-glutamine additives (77). Hepatocyte maintenance medium was changed every 
other day and experiments were performed within 1-2 weeks after cell arrival to the 
lab. 
2.4. Transient transfections 
2.4.1. HuH-7 transfections with FXRE response element 
T2s flasks of HuH-7 cells were transiently transfected with 5 µg of p(FXRE)4-TK-luc 
reporter plasmid and 0.5 µg of Renilla luciferase expression plasmid (pRL-CMV) 
(Promega), using FuGeneHD transfection reagent (Roche, Brandford, CT), 
Lipofectamine2000 transfection reagent (Invitrogen/GIBCO) or Polyethylenimine 
(PEI) with an average MW of 25 kDa (Polysciences, Inc, Warrington, PA); a lmg/mL 
stock solution of PEI was made in 20 mM HEPES buffer. The following transfection 
13 
ratios (µL reagent: µg DNA) were used for each type of transfection: 
reagent 
HD (3 ·1) Lipofectamine2000 (3.5:1), or PEI (4:1). Transfections were fuGene · ' 
perfonned in serum-free media for 6-24 hours. In addition to the reporters, 1.25-2.5 µg 
of emerald green fluorescent protein (pEGFP-Cl) (Clontech, Mountain View, CA) was 
transfected into the cells to monitor transfection efficiency. Transfected HuH-7 cells 
were then trypsinized and re-seeded into a 96-well plate and treated for 24 hours. The 
60 GABA-ergic compounds (Table 1) were screened using single-well treatments. 
Cotreatments of CDCA with FGIN-1-27, FGIN-1-43, and PKl 1195 were balanced 
with equal amounts of solvent control, DMSO. Luciferase activity was measured using 
Dual-Glo Luciferase Reporter kit (Promega) on a GloMax 96 Microplate 
Luminometer (Promega). The luminescence from the firefly luciferase was normalized 
to the Renilla luciferase luminescence to control for transfection efficiencies and for 
well-to-well variation in cell numbers. The ratios of the measurements were calculated 
and reported as mean fold change relative to DMSO (control) ± standard error of the 
mean (SEM) (when greater than two replicates were performed). 
2.4.2. Exogenous FXR expression 
For exogenous expression ofFXR in HuH-7 and ZR-75-1 cells,1.25 µg of3 .1-FXR 
was transfected along with p(FXRE)4-TK-luc, Renilla, and pEGFP-Cl. As a control, 
cells were also transfected with 1.25 µg of pcDNA3 .1 ( +) empty vector in place of 3 .1-
FXR. 
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3 Mammalian two-hybrid assay 2.4 . . 
k f COS-1 cells were transfected with 5 µg pFR-Luc reporter plasmid, 1.5 µg r 25 flas so 
of pM-SRC-1 construct, 1.5 µg of VP16-FXR LBD, 0.5 µg pRL-CMV, and 1.5 µg 
pEGFP-Cl. Transfected COS-1 cells were trypsinized then re-seeded into 96-well 
plates, treated, and luminescence measured using Dual-Glo, as described in section 
2.4.l. 
2.4.4. FXR Mutants 
Point mutations of single amino acids of FXR, generously provided by Dr. Ruitang 
Deng, were formed using a QuikChange site-directed mutagenesis kit (78,79). The 
mutation sequences are listed in Table 2. ZR-75-1 cells were seeded into 6-well plates 
and transiently transfected with 1 µg p(FXRE)4-TK-luc, 100 ng pRL-CMV, 200 ng 
pEGFP-Cl, and 500 ng of 3 .1 ( + ), 3 .1-FXR, or hFXR mutant per well. The cells were 
trypsinized and each well of a 6-well was re-seeded into a portion of a 96-well plate, 
treated for 24 hours and read on the Microplate Luminometer, as described in section 
2.4.1. 
2.5. Real-time RT-PCR 
HuH-7 cells were seeded into 12-well plates and each well was treated with a different 
compound for 24 hours. Similarly, the human hepatocytes were obtained in 12-well 
plates and treated after 4-6 days of routine maintenance. Following the protocol from 
lnvitrogen/GIBCO, total RNA was harvested from the cells using TRizol reagent. The 
RNA was reverse transcribed into cDNA using a High Capacity cDNA Reverse 
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. t' n kit (Applied Biosystems, Carlsbad, CA). cDNA was subjected to gene-
rranscnp 10 
'fi mplification of FXR target genes using SYBR Green PCR Master Mix 
spec1 1c a 
(Applied Biosystems). Reactions were made 50 µL at a time with 25 µL of 2x SYBR 
Green PCR master mix, 21 µL of nuclease free water, 1 µL each of the 10 µM forward 
and reverse primers, and 2 µL of cDNA (4 ng/µL). The actin, BSEP, CYP7Al, FXR, 
HNF4a, and LRH-1 primers were from Eurofins MWG Operon (Huntsville, AL), and 
RXRa primers were from Integrated DNA Technologies (Coralville, IA) (see 
sequences in Table 3). Each 50 µL reaction was split into 2 wells in a 96-well plate to 
provide technical replicates. RT-PCR SYBR Green amplification was performed using 
a 7500 Real-Time PCR System from Applied Biosystems with thermocycling as 
follows: 2 minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. All values were normalized to actin, due to its 
ubiquitous and constant expression in all cells, and were reported as fold change 
relative to mean DMSO (control)± SEM. Applied Biosystems v2.0 SDS software was 
used for analysis; auto threshold and auto baseline settings were used to ensure that 
the optimum analysis settings were used for all reactions. Threshold values were set in 
the exponential phase of the change in normalized reporter dye fluorescence (~Rn). 
The baseline of each sample was set to eliminate background noise from the 
measurements. 
2.6. Molecular modeling 
To further investigate the docking of compounds in the LBD of FXR, in silica 
molecular modeling with Scripps Research Institute's (La Jolla, CA) AutoDock v4.2 
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fi ed on CDCA, PKl 1195 and several FGIN-1 compounds. The crystal was per orm 
f FXR was obtained from the Protein Data Bank (PDB.org) (PDB ID code structure o 
3BEJ) (80). The structure had 237 residues (amino acids 235-472) of the LBD 
crystallized with Merck FXR agonist # 1 (MF A-1) that occupied the pocket in an 
active conformation, with a small fragment of SRC-1 (residues 676-700) that was 
bound to the AF-2 domain (helix 12) of FXR. The coordinates for residues 235-243 
and 472 of FXR were missing and not accounted for. 
Using Discovery Studio Visualizer v2.5 (Accelrys, San Diego, CA) the protein crystal 
structure was inspected and cleaned of any misplaced or misinterpreted atoms. Polar 
hydrogens were added to each amino acid to complete the valance of each atom (non-
polar hydrogens were implied). The valence of charged amino acids was adjusted so 
the overall charge on each residue was an integer, e.g. the guanidine group on arginine 
was given two hydrogens per nitrogen so a neutral charge resulted. Since the protein 
was only a portion of FXR, the end residues were adjusted to mimic the N-terminal 
and C-terminal for the purposes of docking. The ·N-terminal nitrogen of Glu244 was 
allowed two hydrogens to make a + 1 charge and the C-terminal Val4 71 was given a 
hydroxyl group to complete the carboxylic acid to make a -1 charge. These changes 
allowed the polar hydrogens and gasteiger charges to be added to the protein without 
errors in AutoDock Tools v4.2 (ADT). Polar hydrogens were added to the 3D 
coordinates of the ligand chemical structures generated from SMILES strings in 
Discovery Studio. One of the main advantages of AutoDock was that full ligand 
flexibility was possible for docking to static or partially flexible macromolecules (81 ). 
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unds in this study, the number of torsions were as follows: FGIN-1-27, 
for compo 
FGIN-l-43, FGIN-1-51 all had 14 torsions, FGIN-1-20 had 8 torsions, PKl 1195 had 5 
. and CDCA had 7 torsions. A grid box was positioned over the ligand-binding 
torsions, 
pocket with a box size of 50 x 36 x 36 with one grid unit equal to 0.375 A. Map files 
were formed for each atom type within the ligand (all contained different heteroatoms 
O, F, Cl, N) with the FXR LBD structure using AutoGrid. This file contained the 
position characteristic of every atom so the grid map calculations were represented for 
each ligand. 
Each ligand was started in a random position within the grid box. The Lamarckian 
genetic algorithm parameters were as follows: genetic algorithm (GA) runs (100 or 
200), population size (150), maximum number of evaluations (2,500,000), and 
maximum number of generations (27,000). The local search parameters were as 
follows: number of local search runs (50), maximum number of iterations (300), and 
probability of any particular phenotype being subjected to local search (0.01 ). To 
allow for accurate energy calculations, the number of evaluations must increase for the 
number of ligand torsions. Increasing the number of GA runs with 2,500,000 
evaluations per run allowed for more accurate calculations. Due to computational 
constraints, the GA runs were performed 100 or 200 runs at a time, 800 total for the 
FGIN-1 compounds and 600 total for CDCA and PKl 1195, the resulting docking log 
files were then combined by opening groups together in ADT and reclustering at 2.0 A 
root-mean-square (RMS). Clusters containing fewer conformations than the 
detennined rand b . . 
om num er value were disregarded ( calculat10n: # GA runs I # of 
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_ ndom value). Therefore, clusters that contained very few conformations 
clusters - ra 
11.kely formed by random chance. Average binding energies for each cluster were more 
~ ed at random were calculated and graphed as histograms. The conformations 
not 1orm 
with the lowest binding energies were evaluated for possible hydrogen bonding using 
Discovery Studio's hydrogen bond monitor default parameters. Additionally, van der 
Waals interactions were measured using the intermolecular neighbor monitor in 
Discovery Studio. The distance between atoms in each residue and each ligand were 
further analyzed. The van der Waals interactions were calculated by addition of the 
radii of atoms in the ligand and surrounding amino acid atoms with the following radii 
values: carbon-1.87 A, nitrogen-1.50 A, oxygen-1.40 A, hydrogen 1.10 A, fluorine-
1.47 A, chlorine-1.75 A, and sulfur-1.85 A. 
2.7. Statistical analysis 
Individual values of luciferase assay replicates were analyzed using Student's t-test. 
The mean, SEM, n values were used to determine significance of RT-PCR values also 
using Student's t-test. A Grubbs' outlier test was . used on all replicate values prior to 
mean calculations. Differences were deemed statistically significant differences where 
pS0.05. 
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1 TSPO ligands bind also to FXR 3. 
J.J.1 GABA-ergic library screen 
3.RESULTS 
Since many chemical compounds bind to both GABA receptors and TSPO, we 
screened a GABA-ergic chemical library (compounds are listed in Table 1), which 
contained specific TSPO ligands (F series), to examine the overlapping involvement 
of TSPO ligands binding also to FXR. In this screening assay, agonist ligand binding 
to FXR drove the expression of an IR-1 regulated luciferase reporter gene. In the 
library screen (Fig. 3A), one compound, F2 (FGIN-1-27), increased luciferase 
expression considerably compared to the control. This increase was similar to that 
observed with CDCA treatment. Conversely, two compounds structurally similar to 
FGIN-1-27 that are TSPO ligands also, FGIN-1-43 (F3) and PK11195 (FlO), did not 
increase luciferase expression. Since the FGIN-1 compounds were previously shown 
to be a selective ligand of TSPO (73,74) and PKl 1195 is a known ligand (31,70,71), 
these compounds were still included in further experiments for comparison. The 
chemical structures of the FGIN-1 compound contain the same 2-aryl-indole-3-
acetamide backbone with varying halide substitutions and hydrocarbon tail lengths. 
PK11195 has similar aryl ring structures to the FGIN-1 compounds with chlorine on 
the phenyl ring. These compounds are quite structurally different from CDCA as seen 
in Figure 3B (the carbons of CDCA are numbered to correspond with the text). 
20 
12 Coactivator recruitment 3 . . . 
. d' tor that a compound is a ligand of a nuclear receptor is their ability to One m 1ca 
. activators. In the presences of an agonist ligand, the histone 
recruit co 
acetyltransferase, SRC-1, is recruited to the LBD of FXR (82,83). To further validate 
that these compounds bind to FXR, a mammalian two-hybrid assay was used to 
demonstrate coactivator recruitment to a ligand-activated FXR (Fig. 4). CDCA at 10 
µM and 100 µM significantly increased luciferase expression compared to the control, 
signifying coactivator recruitment. Similarly, FGIN-1-27 at 5 µM and 10 µM also 
significantly recruited SRC-1 to the LBD. FGIN-1-27 displayed maximum agonist 
activity at 5 µM - 10 µM. Interestingly, PKl 1195 significantly decreased luciferase 
expression compared to the control, indicative of decreased basal SRC-1 recruitment. 
3.2. HuH-7 hepatoma cell line expresses endogenous FXR 
Human hepatocytes are the ideal cell type for in vitro studies of liver pathology and 
physiology studies, but cannot be easily obtained in large numbers because of limited 
availability of healthy donors. Therefore, we examined two cell lines as alternatives to 
primary hepatocytes. Our results showed that the HuH-7 cell line expressed similar 
amounts of endogenous FXR mRNA compared to human hepatocyte case HH1498 
(Fig. 5A). ZR-75-1 breast cancer cell line, on the other hand, expressed very little 
FXR compared to HH1498. ZR-75-1 was chosen as a good cell line to use for FXR 
over-expression studies that required limited endogenous FXR interference. All cell 
lines tested expressed similar amounts of RXRa, with no significant difference 
compared to HH1498. HuH-7 cells expressed very little endogenous SHP but did not 
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lack LRH-1 or HNF4a expression (Fig. SB). In HuH-7 cells, both CDCA and FGIN-1-
27 significantly increased IR-1 driven luciferase expression in the presence and 
Of exogenous FXR (Fig. SC), while FGIN-1-43 did not modulate luciferase absence 
. ·ty There was a significant increase in luciferase expression when ZR-7 S-1 cells 
acttv1 . 
were treated with CDCA and FGIN-1-27 in the presence of exogenous FXR (Fig. SD). 
No change occurred from treatments in the ZR-7S-l cells in the absence of exogenous 
FXR. 
3.3. FGIN-1-27 is a partial agonist of FXR; PK1119S and FGIN-1-43 are antagonists 
To further explore the binding of TSPO ligands to FXR, we examined the effects of 
FGIN-1-27, FGIN-1-43 and PK1119S on CDCA-activated FXR. Figure 6 represents 
the binding properties of these compounds in different combinations of treatments at 
varying concentrations. As expected, CDCA and FGIN-1-27 increased luciferase 
expression alone at all concentrations. Our study showed that FGIN-1-27 (10 µM), 
FGIN-1-43 (10 µM) and PK1119S (10 µMand 1 µM) decreased luciferase expression 
of COCA-activated FXR at 1 OOµM. However, when CDCA was limiting (::S 10 µM), 
FGIN-1-27 further activated FXR and exhibited an additive effect with CDCA. When 
COCA was at 100 µM, FGIN-1-27 (10 µM) significantly decreased transcription, 
acting as a partial agonist. Additionally, FGIN-1-43 (10 µM) antagonized CDCA at 
100 µM and was not an agonist alone. When CDCA concentration was limiting, 
FGIN-1-43 had no effect on CDCA-activated FXR; however, FGIN-1-43 (10 µM) did 
decrease luciferase expression due to FGIN-1-27 agonist effects at 10 µMand 1 µM. 
PK1l l95 (10 µM) decreased FXR activation by CDCA at 100 µM, 10 µM, 1 µMand 
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100 nM. pKll 195 alone significantly decreased basal transcription levels at 1 O µM. 
d.. lly PKll 195 at both 10 µM and 1 µM decreased FGIN-1-27-activated (1 Ad 1tiona , 
µM and 10 µM) luciferase expression. 
J.4. Effect of compounds on genes downstream of FXR 
3.4.1 Changes in BSEP and SHP expression 
Another way to measure transcriptional effects of a compound on a nuclear receptor is 
to look at regulation of specific downstream target genes. FXR ligands directly 
increase transcription of downstream genes, including BSEP and SHP (84). In our 
studies, FGIN-1-27 increased mRNA expression of both BSEP and SHP in human 
hepatocytes (cases HH1486 and HH1498) and HuH-7 cells similar to levels seen with 
COCA treatment, while FGIN-1-43 did not increase basal expression(Fig. 7 and 8). 
Cotreatments of FGIN-1-43 or PKl 1195 with CDCA and FGIN-1-27 did not 
significantly decrease BSEP mRNA expression in HH1498 (Fig. 7); however, similar 
to the luciferase FXRE results in HuH-7 cells, FGIN-1-43 did significantly repress 
BSEP and SHP expression induced by FGIN-1.:.27 ligand binding, but not CDCA. 
PKll 195 did not repress CDCA or FGIN-1-27 induced BSEP mRNA expression in 
HuH-7 cells or in HH1498. Conversely, FGIN-1-43 and PKl 1195 increased SHP 
mRNA expression when combined with CDCA in HH1498 (Fig. 8) . PKll 195 also 
increased SHP expression when combined with FGIN-1-27 in HH1498. In HH1498, 
PKl 1195 alone increased mRNA expression of both BSEP and SHP. 
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Changes in CYP7 Al expression 3.4.2. 
h downstream target gene of FXR is CYP7A1, though the gene is indirectly Anot er 
l t d. COCA indirectly represses CYP7A1 expression through a SHP mediated regu a e , 
pathway (56). Results show that both COCA and FGIN-1-27 significantly repress 
CYP7Al expression in human hepatocytes (Fig. 9). FGIN-1-43, on the other hand, 
does not alter basal expression of CYP7 Al . Unfortunately, CYP7 Al expression 
studies in HuH-7 cells yielded inconsistent results (data not shown), most likely due to 
the low expression of SHP (Fig. 5B). In another study, we also showed that PKl 1195 
significantly repressed CYP7Al expression in HH1498, but to a lesser extant than the 
effects seen by COCA and FGIN-1-27 (Fig. 9) . 
3.5. TSPO ligands bind to the LBD of FXR 
To further explore the capacity of PKl 1195 and 4 FGIN-1 compounds to fit into the 
LBD of FXR, in silico molecular modeling was performed. Docking results verified 
that these TSPO ligands could fit into an active conformation of FXR. The crystallized 
structure of human FXR (PDB ID code 3BEJ) (80) was used as the template to study 
the binding properties of COCA, PKl 1195, and 4 FGIN-1 compounds. This template 
was among 9 crystallized structures of FXR in the PDB, all of which had a ligand and 
coactivator bound, except for 1 OSH, which lacked a coactivator. Although this 
template has been used for other docking experiments (78), 1 OSH also lacked a 
significant portion of helix 3, and therefore was not an ideal candidate. Two of the 
structures were isolated from rat FXR, differing from human FXR by only 12 amino 
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. b t r0 r the purpose of this study, only human FXR was relevant. Of all of the acids, u 1' 
rystallized structures, 3BEJ chain B was the most complete structure with the human c 
lowest b-factors in the binding pocket, so it was the best choice. B-factors are a 
measure of the disorder in the x-ray diffraction pattern caused by temperature-
dependent vibrations, and so provide a measure of confidence in the accuracy of each 
atom's coordinates. MFA-1 formed an active conformation in the crystal structure, co-
crystallized with a 24 amino acid fragment of SRC-1 bound to helix 12 of FXR (80) 
(Fig. 10). For each theoretical conformation generated by AutoDock, an estimate of 
the free energy of binding was calculated by the following formula: [final 
intermolecular energy (van der Waals, H-bond, desolvation energy + electrostatic 
energy)]+ [final total internal energy] + [torsional free energy] - [unbound system's 
energy]. The lower the free energy of binding, the more energetically favorable the 
conformation. 
3.5.1. Docking ofCDCA 
CDCA was allowed to have seven rotatable bonds so only 600 GA runs were 
necessary to reach a state of no further refinement. At 2.0 A RMS clustering restraints, 
ADT formed eight conformational clusters with estimated free energy of binding 
ranging from -10.43 kcal/mol to -8.51 kcal/mol. The majority of conformations fell 
into two of the eight conformational clusters; the other 6 contained fewer 
conformations than the random number value (600/8 = 75) so they were disregarded 
from further analysis. The largest cluster contained 493 conformations with an average 
b" d" 
m mg energy of -9.75 ± 0.009 kcal/mol (conformation a). The second largest cluster 
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bad 75 confonnations with an average binding energy of -9.45 ± 0.028 kcal/mol 
c nnation b) (Fig. 1 lA). Conformation a oriented the carboxyl group on C24 of (con10 
COCA near T288 to form hydrogen bonds (hydroxyl oxygen 2.39 A, hydroxyl 
hydrogen 1.88 A, carboxyl oxygen 1.77 A). In a flipped orientation (conformation b), 
the COCA carboxyl group hydrogen bonded to Arg331 (2.16 A) and the oxygen of C7 
hydrogen bonded to H447 (2.20 A). Not surprisingly, CDCA in conformation a fit an 
orientation similar to MFA-1 (Fig. 10), which is a CDCA analog with an additional 
phenyl ring at C21 and a carboxyl group at C3 (80). Results show CDCA in both 
conformations was able to form van der Waal interactions with 13 residues on helices 
3, 5, 10/11 and 12. 
3.5.2. Docking of FGIN-1-2 7 
Although structurally quite different from CDCA, FGIN-1-27 is a very hydrophobic 
molecule and also fit into the ligand-binding pocket of FXR with inhibition constants 
in the nanomolar range. From 800 GA runs, where free energy of binding ranged from 
-10.23 kcal/mol to -5.80 kcal/mol, ADT formed 102 conformational clusters at 2.0 A 
RMS clustering restraints, 77 of which contained fewer conformations than the 
random number value (800/102 = 7.8), so were most likely reflected background 
noise. Although AutoDock 4.2 allows flexible ligand docking to bind to a fixed 
protein, increasing ligand flexibility (> 1 O torsional degrees of freedom) decreases 
consistency of the conformation clusters (81). FGIN-1-27 was fully flexible with 14 
torsional bonds that rotated freely, compared to CDCA, which only had seven. This, in 
part, explained the greater number of clusters generated despite the greater number of 
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Closer inspection of the conformational clusters revealed that many clusters GA runs. 
d ·milar positions of the core ring structure, with the majority of variations share s1 
Clusters being accounted for by the numerous positions adopted by the between 
flexible hydrocarbon tails. For the FGIN-1 compounds, additional analysis was 
performed to identify four major conformations based upon position of the core ring 
structure only. As seen in Figure 1 lB, of the 25 non-random clusters of FGIN-1-27, 
41% represented conformation a, where fluorine formed a hydrogen bond with T288 
(I.97 A). One study showed that fluorine attached to an aromatic carbon can form a 
hydrogen bond when the protein's donor atom is at an average distance of 2.698 A 
(85). 20% of the clusters (conformation b) positioned fluorine close enough to 
hydrogen bond to Y369 (2.44 A). The other two conformations (20% c and 18% d) 
oriented the rings perpendicular to the pocket. Similar to CDCA, FGIN-1-27 was most 
likely held in place in the LBD by van der Waals interactions with 16-18 residues on 
helices 3, 5, 6, 7, 10/11, and 12. 
3.5.3. Docking of FGIN-1-20 
Analogs of FGIN-1-27 were also docked into FXR to examine the significance of 
fluorine and the hydrocarbon tails to the binding properties. When the hydrocarbon 
tails were shortened from hexyls to propyls in FGIN-1-20 (Fig. 11 C), the number of 
torsions decreased by 6, resulting in fewer overall conformational clusters. From 800 
GA runs of FGIN-1-20, free energy of binding ranged from -9.64 kcal/mol to -7.79 
kcaVmol. ADT formed 35 conformational clusters at 2.0 A RMS clustering restraints, 
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28 of which contained fewer conformations than the random number value (800/35 = 
9) Similar to FGIN-1-27, fluorine in conformation a hydrogen bonded to T288 22. . 
(l .94 A) but with an increased occurrence of 60%. The shorter tails limited FGIN-1-20 
from fitting into conformation band favored conformation cat 34%. Additionally, the 
oxygen in conformation c formed a hydrogen bond with H447 (2.14 A). FGIN-1-20 
had lower average binding energies for each cluster compared to FGIN-1-27. No 
conformationdwas formed. FGIN-1-20 still interacted with 13 amino acids of helices 
3 5 6 7 and 10/11, which were most likely allowed for hydrophobic interactions. 
' ' ' ' 
3.5.4. Docking of FGIN-1-51 
The loss of the fluorine in FGIN-1-51 (Fig. l lD) caused no difference in orientation 
compared to FGIN-1-27, and had a similar binding fingerprint. FGIN-1-51 was run 
800 times and reclustered at 2.0 A RMS clustering restraints forming 111 
conformational clusters. Free energy of binding ranged from -10.44 kcal/mol to -6.52 
kcal/mol. Of these 111 clusters, 24 contained fewer than the random number value 
(8001111 = 7 .2) of conformations so they cannot be distinguished from background. 
FGIN-1-51 favored conformation b and decreased the overall average binding 
energies per cluster compared to FGIN-1-27 and FGIN-1-20. The absence of fluorine, 
however, prevented FGIN-1-51 from forming hydrogen bonds with any of the residues 
in the LBD. 
3.5.5. Docking of FGIN-1-43 
The structure of FGIN-1-43 differed from FGIN-1-27 only by lacking fluorine and 
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. two chlorines. FGIN-1-43 also was allowed 14 torsions so 800 GA runs possess mg 
essary The range of free energy of binding values was much larger than for were nee · 
any of the other FGIN-1 compounds, from -12.30 kcal/mol to -1.55 kcal/mol. From 
first evaluations, 152 conformational clusters were formed; 116 contained fewer than 
the random number value (800/152 = 5.3) of conformations so they were considered to 
be background and unlikely to be significant. FGIN-1-43 in Figure 1 lE had similar 
orientations to FGIN-1-27 but showed a greater range of binding energies overall and 
the most variation within each cluster, creating larger SEM than the other FGIN-1 
compounds. Despite the differences in binding energies, FGIN-1-43 only varied in 
conformation from the other FGIN-1 compounds in conformation b because the 
chlorophenyl ring did not fit close to Tyr369. Of FGIN-1-43's 36 clusters non-
background clusters, 40% were in conformation c, 29% in conformation d and the 
remaining 31 % split between conformations a and b. Even with the higher binding 
energies, it is still theoretically possible for FGIN-1-43 to interact with 17 residues on 
helices 3, 5, 6, 7, and 10/11 in an energetically favorable fashion. 
3.5.6. Docking of PKJ 1195 
The most well known TSPO ligand, PKl 1195, was also docked into the LBD of FXR. 
Since PKl 1195 only had 5 possible flexible torsions, fewer GA runs were required to 
reach optimal refinement. Out of 600 GA runs ADT formed 9 conformational clusters 
' 
for PKl 1195 with free energy of binding ranging from -9 .94 kcal/mol to -8.81 
kcaVmol. Of these 9 clusters, 8 contained fewer than the random number value of 
conformations (600/9 = 66.7) so they were considered background binding. The 
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1 ster contained 496 conformations represented by an average binding energy largest cu 
of-9.64 ± 0.005 kcal/mol. Figure 1 lF shows that PKl 1195 adopted only one possible 
~ nnation within the pocket with no possibility or opportunity to form any 
con10 
hydrogen bonds, but was close enough to form hydrophobic interactions with 17 
amino acids on helices 3, 5, 7, 10111, and 12. 
3.5. 7. Mutational studies of FXR 
Since the molecular modeling studies were based on a fixed crystal structure, as 
opposed to a fully flexible molecule in a biological environment, point mutations 
formed in FXR were necessary to validate the studies. Only CDCA and FGIN-1-27 
were examined due to their capacity to hydrogen bond. (Though FGIN-1-20 was also 
able to form a hydrogen bond, this compound is not commercially available). Figure 
12A shows the conformations of CDCA and FGIN-1-27 explained above. The 
docking studies demonstrated that these compounds formed hydrogen bonds with 
Thr288 (helix 3), Arg331(helix5), Tyr369 (helix 7) or His447 (helix 10/11), so single 
amino acid mutations of these residues were fo~med (Table 2). Ser332 is the only 
other residue in the pocket that could form hydrogen bonds with side chain atoms so a 
mutation was also created for this residue as another potential key residue. As a 
control, ZR-75-1 cells were evaluated with and without exogenous FXR to compare to 
changes caused by mutated residues. In each mutation, the basal activation of FXR 
was decreased compared to the wild-type FXR transfection. Both CDCA and FGIN-1-
27 hydrogen bonded to T288 in silico; when threonine (T288L) was mutated, 
activation by CDCA decreased to basal while FGIN-1-27 decreased by about half. 
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Only COCA in conformation b hydrogen bonded to R331, so as expected, the arginine 
mutation (R331L) prevented CDCA-induced expression, whereas FGIN-1-27 was not 
affected. Conformation b of FGIN-1-27 hydrogen bonded to tyrosine 369, but Y369L 
mutation resulted in a gain of function for FGIN-1-27. As expected, the Y369 
mutation showed no change in CDCA. As predicted for CDCA in conformation b, the 
histidine mutation (H447F) prevented luciferase expression. The H447F mutation 
decreased activity also in response to FGIN-1-27. Even though no hydrogen bonding 
was seen with Ser332, the mutation (S332F) decreased luciferase activity also with 
both COCA and FGIN-1-27 treatments. 
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4. DISCUSSION 
FXR is involved in multiple aspects of the maintenance of bile acid homeostasis acting 
as a mediator between bile acid synthesis and efflux from the liver (8). The alternative 
pathway of bile acid synthesis requires TSPO for the trans location of cholesterol into 
the mitochondria (29). Since both FXR and TSPO are important for maintaining bile 
acid homeostasis, it is not improbable that a single compound modulates the activity 
of each of these proteins. We first looked at a GABA-ergic chemical library in order to 
identify chemical treatments, already known as TSPO ligands, that increase 
transcription of an FXR-regulated luciferase reporter. We identified one compound, 
FGIN-1-27, that activated FXR to a level similar to CDCA (Fig. 3A). FGIN-1-27 was 
one of the specific TSPO ligands in the F series of compounds in the chemical library; 
therefore, we chose two other structurally similar TSPO ligands (FGIN-1-43 and 
PKl 1195) to investigate further. 
Our studies show that FGIN-1-27 is a partial agonist of FXR (Fig. 6). We show 
through in vitro luciferase reporter gene assays that treatment of FGIN-1-27 activates 
FXR-mediated transcription but decreases FXR activation by CDCA when CDCA 
concentration is not limiting (100 µM) . Even though the FXR ligand-binding pocket 
preferentially binds amphipathic, non-planar bile acids that allow polar entities to form 
hydrogen bonds with amino acid residues (86), FGIN-1-27 fits into this pocket also. 
Based on the size of the pocket and of the individual molecules, it is unlikely that both 
COCA and FGIN-1-27 bind to the pocket at the same time. According to in silica 
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I odeling results, FGIN-1-27 fits into the pocket with low binding energies, inolecu arm 
bl to those of CDCA (Fig. 1 lA and 1 lB). Both CDCA and FGIN-1-27 compara e 
bond to the same amino acid (T288) in silica, and show no FXR-activation hydrogen 
when H44 7 is mutated into phenylalanine (Fig. 12), which shows that both compounds 
bind similarly inside the pocket and compete for binding positions. Because CDCA 
bas more atoms that can form hydrogen bonds, compared to FGIN-1-27, CDCA can fit 
into the binding pocket in more than one favorable position with more favorable 
agonist binding. This is evident when CDCA (100 µM) is treated with FGIN-1-27 (10 
µM); FGIN-1-27 antagonizes the effects of CDCA. However, when FGIN-1-27 and 
COCA are both at 10 µM, FGIN-1-27 binding is the main factor contributing to the 
increase in reporter gene transcription. Under normal circumstances, however, CDCA 
concentration would rarely reach 100 µM, as seen in a study of bile acid 
concentrations in the liver (87), where the average concentration of CDCA was 45 µM 
(30 nmollg)2. Only with gallstone obstruction did the CDCA concentration reach 96 
µM (64 nmol/g). Therefore, treatment with FGIN-1-27 in vivo would be predicted to 
show only agonist effects on FXR. 
In this binding study, CDCA fits into the FXR ligand-binding pocket, with 87% of the 
possible conformations oriented so the C-24 carboxylate group hydrogen bonds with 
Thr288 (Fig. l lA and 12A). The ?a-hydroxyl group of CDCA in the remaining 13% 
of the conformations hydrogen bonds with H447 and the C-24 oxygen binds to 
Arg33 t. In accordance with modeling studies performed by other groups, CDCA 
2Th. 
is calculation was based on a 1.5 kg adult liver 
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. .t elf similarly by positioning the 3a-hydroxyl group near His44 7, allowing the 
onents is 
C-24 carboxylate group to hydrogen bond to Arg331 (86), or it is oriented so the C-24 
carboxylate oxygens hydrogen bond to Leu348 (78). The results of this study position 
COCA (conformation a) in an orientation more similar to that typically adopted by 
steroid hormones, and MFA-1, with the steroid rings rotated so that the 3a-hydroxyl 
group is near Arg331 (Fig. llA). 
It is possible that there is more than one functional orientation of CDCA in the LBD 
that can cause agonist ligand effects from hydrogen bonding to more than one residue. 
Our point mutation studies of FXR show that Thr288, Arg331 and His44 7 were the 
key residues responsible for the agonist effects of CDCA (Fig. 12B), all of which 
Conned hydrogen bonds in silica. This suggests that the ?a-hydroxyl and C-24 
oxygens are key attributes for CDCA. Our studies are in agreement with other studies 
that have shown the 3a-hydroxyl group, present on all bile acids, is not necessary for 
FXR activation (86) and an oxygen in either a carboxyl group or an alcohol on C-24 is 
responsible for the enhanced ligand potency (88). It is most likely a combination of the 
hydrophobicity of CDCA and available oxygens to form hydrogen bonds that confers 
agonist-binding properties, and allows CDCA to bind in more than one conformation. 
Although the FXR ligand-binding pocket evolved to recogmze non-planar 
amphipathic bile acids (86), FXR is able to bind compounds also with planar 
components, such as the FGIN-1 compounds. All four FGIN-1 compounds subjected 
to in silica modeling fit into four main conformations, a, b, c and d (Fig. 1 lB-1 lE). 
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th h the orientations within the pocket are similar, the ranges of binding energies Al oug 
vary among the FGIN-1 compounds. Since the FGIN-1 compounds have the same 
tructure there may be no discrepancy in the initial recognition of the compound cores ' 
by FXR, however, once inside the pocket differences in binding occur. Removal of the 
fluorine from FGIN-1-27 (FGIN-1-51) did not inhibit binding inside the pocket of 
FXR (Fig. llD). This suggests that the fluorine is not necessary for FGIN-1-27 to 
enter the pocket, but it could still be responsible for its agonist effects. The fluorine in 
FGIN-1-27 hydrogen bonded to Thr288 and Y369 in silica, however, mutational 
studies show that Tyr369 is not responsible agonist effects of ligand binding of FGIN-
1-27 and Thr288 only decreased FXR-activity by about half. This discrepancy may be 
due to the dimensions of the crystallized pocket formed by MF A-1 (Fig. 10), not truly 
reflecting a biologically active flexible protein. The majority of the conformations of 
all these compounds docked fit into an "L" shape configuration with the bottom of the 
"L" pointing towards Thr288. The phenol group on MF A-1 most likely formed an 
additional crevice in the protein allowing ligands to bend when docked into the crystal 
structure, even though the 3BEJ structure closely · resembled that of a rat receptor 
structure crystallized with 6-ethyl-CDCA (80). In a non-computerized environment 
where the entire protein can be flexible, this pocket may not form with all ligands. In a 
constantly flexible cellular environment, it is possible that the fluorine of FGIN-1-27 
in conformation c could hydrogen bond to His44 7. This would correlate with the 
mutation of His447 diminishing FXR-activation by FGIN-1-27 (Fig. 12B). Upon entry 
into the pocket, it is conceivable that the FGIN-1 compounds would favor 
conformations c or d and never bend into an "L" shaped conformation. When Arg331 
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t d l·nto Ieucine little change is seen in FGIN-1-27 activity compared with is muta e ' 
wild-type FXR (Fig. 12B). If FGIN-1-27 was in conformation d, fluorine could 
· ably hydrogen bond to the arginine, however, since Arg331 seems to have no 
conce1v 
significant interaction with FGIN-1-27, conformation c with the fluorophenyl group 
near His447 is more probable. Although the mutation of Ser332 (S332F) eliminates 
FXR-activation by treatments of both CDCA and FGIN-1-27, the addition of the 
bulky phenylalanine residue is most likely large enough to block the entrance to the 
binding pocket preventing any ligand entry. 
To examine whether the hydrocarbon tails were factors in the binding of the FGIN-1 
compounds, FGIN-1-20 was subjected to evaluation (Fig. llC). The original study 
with the FGIN-1 compounds (72) found the binding affinity to TSPO increased with 
increasing alkyl chain lengths, up to 6 carbons. In this study, however, decreasing the 
number of carbons on the hydrophobic tails minimally changes the binding 
orientations in conformations a and b, with little difference in binding energies. 
However, the longer hydrophobic carbon tails in the other FGIN-1 compounds that 
fold alongside the indole backbone in conformations c and d create hydrophobic 
interactions favorable for ligand binding. The binding orientation changes when 3 
carbons from each tail are removed; FGIN-1-20 does not fit into conformation d. 
Additionally, the oxygen on FGIN-1-20 in conformation c forms a hydrogen bond 
with His447. This orientation is unlikely to occur in structures with long hydrocarbon 
tails, such as FGIN-1-27, because the tails would cause steric hindrance. We did, 
however, see complete elimination of the agonist effects of FGIN-1-27 with the 
36 
8447F mutation of FXR, but this correlates with earlier speculations that the FGIN-1 
ds may favor conformation c upon entry into the pocket with fluorine of compoun 
FGIN-l-Z? hydrogen bonding to His44 7. 
The addition of chlorine does not prevent FGIN-1-43 from fitting into the binding 
pocket of FXR; instead, it only forms unfavorable binding energies (Fig. 1 lE). For 
this compound, conformation c is favored most often. It is possible that the sheer size 
of chlorine prevents FGIN-1-43 from binding efficiently. Interestingly, FGIN-1-43 is 
better at antagonizing the agonist effects of FGIN-1-27 on FXR more so than with 
COCA (Fig. 6). This suggests that FXR can recognize the core indole-acetarnide 
structure without discrimination, but FGIN-1-27 has a higher binding affinity. When 
both FGIN-1 compounds are present, both will go into the pocket, but FGIN-1-27 will 
bind more favorably than FGIN-1-43. Similarly, because FGIN-1-43 does not bind to 
any residues specifically, CDCA will bind more efficiently so FGIN-1-43 will be 
displaced easier in the presence of CDCA. This idea also explains the antagonist 
effects of PKl 1195 on both CDCA and FGIN-r-27. According to the modeling 
results, PKl 1195 fits only into one orientation with an inhibition constant very similar 
to CDCA (Fig. 11 F). Even though PKl 1195 does not interact with any residues 
specifically, it is oriented so access to His44 7 is blocked. When PKll 195 is in the 
presence of an agonist ligand, PKl 1195 could compete for occupancy of the pocket of 
FXR and prevent CDCA or FGIN-1 -27 from binding (Fig. 6). 
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th Studies we had to take into account the possibility of the FGIN-1 compounds In ese ' 
binding to TSPO on the mitochondria to indirectly increase the synthesis of CDCA, 
and in tum, activate FXR. In fact, FGIN-1-43 is found to be a more potent TSPO 
ligand than FGIN-1-27 (72). Ifthere were any downstream effects present, FGIN-1-43 
would show equal, if not more, activation of FXR than FGIN-1-27. In all of the 
results, FGIN-1-43 never activates FXR, thus demonstrating FXR activation by FGIN-
1-27 is not a result of TSPO ligand binding. 
We also show that FGIN-1-27 is as efficient as CDCA in recruiting the coactivator, 
SRC-1, to FXR LBD (Fig. 4). At 10 µM, FGIN-1-27 binding causes greater fold 
increase in luciferase expression than did CDCA treatment at 10 µM. The decrease in 
capability of PKl 1195 to recruit SRC-1 correlates with this compound being an 
antagonist. However, PKl 1195 does not antagonize BSEP and SHP expression as 
expected (Fig. 7 and 8). In fact, cotreatment of PKl 1195 with CDCA and FGIN-1-27 
shows either little change or an increase in BSEP and SHP expression in HuH-7 cells 
and primary hepatocytes. Dussault et al (54) identified synthetic ligands of FXR that 
are gene-selective and modulate SHP and CYP7 Al expression differently. The 
discrepancy in PKl 1195 binding could be explained if the compound possesses 
different antagonistic effects based on the target gene. It is also likely that PKl 1195 
hinds to a number of different receptors. For example, in human hepatocytes, 
PKl 1195 is an agonist of pregnane x receptor (PXR; NRl 12) and an inverse agonist of 
co f . 
ns Itubve androstane receptor (CAR; NR113), both also nuclear receptors (89), 
although HuH-7 cells do not express detectable levels of either PXR or CAR. In 
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I ( 
HH1498, where SHP is not limiting, PKl 1195 treatment causes a significant increase 
in SHP mRNA expression, but PKI 1195 does not inhibit CYP7 Al expression at the 
same level as CDCA or FGIN-1-27 (Fig. 9). Our data shows PKl 1195 has little 
· t effect on FXR alone, therefore, this increase in SHP expression and lack of 
agoms 
full CYP7Al repression could be due to PK11195 binding to LRH-1. If this were the 
e PKl 1195 could prevent SHP from binding to LRH-1, thus eliminating the 
cas' 
repressor function of SHP. Further studies of PKll 195 binding to LRH-1 to cause 
direct transcriptional effects are necessary to validate this theory. 
Jn these experiments, FGIN-1-27 proves to be at least equally as potent a ligand of 
FXR as CDCA at 10 µM, despite inevitable variations between individual hepatocyte 
cases. FGIN-1-27 increases both BSEP and SHP expression significantly, while 
repressing CYP7Al expression, as expected (Fig. 7-9). FGIN-1-43 and PKl 1195 
treatments, however, rarely cause any differences in gene expression from FXR 
activation. With all data considered, we conclude that FGIN-1-43 is a selective 
antagonist, competing only with the ligand with similar binding affinities to itself 
(FGIN-1-27) and PKl 1195 is a non-selective antagonist. 
In addition to showing that these TSPO ligands modulate FXR, we also investigated a 
cell line with non-limiting endogenous FXR and RXR as an alternative to human 
hepatocytes (Fig. 5). Although primary human hepatocytes are the best in vitro 
representation of human liver, they vary among individuals and are expensive and 




Sl·nce they can be cultured in large numbers and passaged repeatedly. 
studies 
Unfortunately, HuH-7 lack SHP, so studies involving CYP7 Al repression through the 
SHP pathway may be difficult. Additionally, we show that the breast carcinoma cell 
. ZR 75-1 has very little endogenous FXR with non-limiting endogenous RXR. 
bne, - ' 
Therefore, this cell line is ideal for mutational studies to avoid the interference of 
endogenous FXR. 
In summary, targeting the rate-limiting step in the alternative pathway would be 
beneficial for upregulating this pathway. Correspondingly, TSPO ligands are known to 
increase cholesterol uptake into the mitochondria, which has been proven to be the 
rate-limiting step for the alternative pathway (29). Although controversial, some 
studies have shown that bile acids do not regulate CYP27A1 expression the same as 
CYP7Al (68,69), which is not surprising since increasing CYP27Al expression does 
not affect bile acid synthesis rates (29). Therefore, upregulating the alternative 
pathway apart from bile acid activation would be beneficial in people possessing 
faulty genes for CYP7 Al because the alternative pathway is heavily relied upon. 
However, in healthy populations an upregulation would not be necessary since the 
alternative pathway contributes little to the overall synthesis (23). 
We have shown that FGIN-1-27 increases FXR transcriptional activity to increase 
BSEP and SHP expression. Also, FGIN-1-27 increases the rate of cholesterol entering 
the mitochondria by binding to TSPO (72). As demonstrated in Figure 13, targeting 
both TSPO and FXR with one compound would increase the bile acid synthesis rate of 
40 
l ative pathway while regulating homeostasis in the liver by controlling the the a tern 
. feedback through FXR. This would occur by 1) FGIN-1-27 binding to TSPO, 
negative 
facilitating the transport of cholesterol into the mitochondria where 2) CYP27 Al 
would initiate the production of COCA. Furthermore, 3) FGIN-1-27 binds to FXR to 
4) increase BSEP expression that would increase the efflux of bile from the liver. As 
bile acids are removed from the liver, the bile acid pool would decrease and trigger 
more synthesis of COCA, thus lowering the cholesterol pool. 
Future studies will be necessary to investigate the changes in the production of bile 
acid intermediates following FGIN-1-27 treatment. Multiple other genes involved in 
bile/lipid homeostasis are activated by FXR, including phospholipid transport protein, 
intestinal bile acid binding protein, and multidrug resistant protein 2 (MRP2) (84). The 
regulation of these genes by FGIN-1-27 should be investigated to further characterize 
FGIN-1-27 as a potential therapeutic drug. Similarly, the liver x receptor (LXR; 
NR1H3) increases expression of CYP7 Al from increased oxysterol production in the 
alternative pathway (90), thus regulating cell cholesterol concentrations. It would be 
necessary also to explore the transcriptional effects of FGIN-1-27 on LXR. Overall, a 
better understanding of the involvement of the mitochondria and FGIN-1-27 (and 
related compounds) in nuclear receptor signaling will lead to possible therapies for 
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6. ABBREVIATIONS 
ADT: AutoDock tools 
Af-2: activation function-2 domain 
BSEP: bile salt export pump 
CA: cholic acid 
CDCA: chenodeoxycholic acid 
COS-1 : African Green Monkey kidney cell line transformed with Simian Virus 40 
CTX: cerebrotendinous xanthomatosis 
CYP7 Al: cholesterol 7a-hydroxylase 
CYP7Bl: 25-hydroxycholesterol 7a-hydroxylase 
CYP8Bl: sterol 12a-hydroxylase 
CYP27Al: sterol 27-hydroxylase 
CYP39Al: oxysterol 7a-hydroxylase 
CYP46Al : cholesterol 24a-hydroxylase 
DMEM: Dulbecco's Modified Eagle Medium 
DMSO: dimethyl sulfoxide 
DR: direct repeat 
ER: everted repeat 
FBS: fetal bovine serum 
FGIN-1: 2-aryl-3-acetamide compounds from Fidia-Georgetown Institute for the 
Neuorsciences (72) 





FGIN-1-27: N, N-di-n-hexyl 2-(4-fluorophenyl) indole-3-acetamide 
FGIN-1-43: N, N-dihexyl 2-(4-chlorophenyl) 5-chloroindole-3-acetamide 
FGIN-1-51: N, N-di-n-hexyl 2-(4-phenyl) indole-3-acetamide 
FXR: famesoid x receptor 
fXRE: FXR response element 
GA: genetic alorithm 
GABA: y-aminobutryic acid 
HH1486: human hepatocyte case #1486 
HH1498: human hepatocyte case #1498 
HMG-CoA: 3-hydroxy-3methylglutaryl-coenzyme A 
HNF4: hepatic nuclear factor-4 
HuH-7: human hepatoma cell line 
IR: inverted repeat 
LDL-C: low-density lipoprotein cholesterol 
LBD: ligand binding domain 
LRH-1: liver receptor homolog-1 
MFA-I: Merck FXR agonist #1 (17~-( 4-hydroxybenzoyl) androsta-3, 5-diene-3-
carboxylic acid) 
OMM: outer mitochondrial membrane 
PKI 1195: 1-(2-chlorophenyl)-N-methyl-N-(1-methylprolyl)-3-isoquinoline 
carboxamide 
PDB: protein data bank 
RMS: root-mean-square 
52 
R)(Ra.: retinoid x receptor 
SHP: small heterodimer partner 
SRC-1: steroid receptor coactivator-1 
STAR: steroidogenic acute regulatory protein 
TK: thymidine kinase 
TSPO: translocator protein (18 kDa), formerly known as peripheral-type 
benzodiazepine receptor (PBR) (91) 
UAS: upstream activation sequence 
ZR-75-1: breast cancer cell line 
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7. FIGURE LEGENDS 
. 1. CYP enzymes involved in the two pathways of bile acid synthesis. ~ initiates t~e classic/neutral pathway to produce_ ~~olic acid (_CA) ~~d 
h odeoxycholic acid (COCA). CYP27Al and CYP46Al mittate alternative/acidic 
c ~~way forming oxysterols that must undergo ?a-hydroxylation before becoming 
roCA. The carbons on cholesterol are numbered to correspond with the names of 
h intermediate formed by each CYP enzyme shown (boxed); changes to each 
::cture are illustrated in red. Note: other non-CYP enzymes are also involved in 
these pathways. 
Figure 2: The role of STAR and TSPO in cholesterol transport into the 
mitochondria. Intracellular cholesterol binds to STAR, and through a complex 
pathway involving other proteins not shown, cho.lesterol _is !ranspo:t:ed to the OMM. 
Cholesterol is then transferred to TSPO where ligand bmdmg facilitates cholesterol 
uptake into the IMM whe~e CYP27 Al resi~es. ~holesterol_ transport i~ the rate-
limiting step in the alternative pathway for bile acid synthesis. COCA will then be 
synthesized once in the liver. 
Figure 3: GABA-ergic chemical library screen of compounds and structures of 
COCA, FGIN-1 compounds, and PK11195. A) HuH-7 cells were transfected with 5 
µg p(FXRE)4-TK-luc and 0.5 µg pRL-CMV and treated for 24h with GABA-ergic 
compounds. Series B-F are single well 10 µM treatments with values reported as fold 
change relative to OMSO (control) (n=4). COCA (n=4) is also 10 µM. F2 is FGIN-1-
27, F3 is FGIN-1-43 and FlO is PK11195. B) Chemical structures of compounds 
mentioned in A. FGIN-1-27 has six carbons on R3 with fluorine at R1 and hydrogen at 
R2. FGIN-1-43 has six carbons on R3 with chlorine at R1 and R2. 
Figure 4: Coactivator recruitment to FXR in mammalian two-hybrid assay. COS-
1 cells were transfected with 5 µg of pFR-luc, 1.5 µg pM-SRC-1, 1.5 µg VP16-FXR 
and 0.5 µg pRL-CMV and treated for 24h. Luciferase activity of each treatment is 
reported as fold change relative to OMSO (control) represented by a solid line at 1. 
•denotes significance compared to control, p::::; 0.05, (n=8). 
Figure 5: Cell line comparison of mRNA expression for proteins involved in FXR-
mediated bile acid homeostasis. A) Expression of FXR and RXR mRNA in human 
hepatocytes, HuH-7, and ZR-75-1 cell lines. Total RNA was reverse transcribed and 
cDNA was subjected to actin and select gene-specific amplification with SYBR green 
PCR. Gene expression was normalized to actin and expressed as fold relative to 
~H1498 mRNA expression (control) (n=2) . B) mRNA expression of nuclear receptors 
mvolved in SHP-mediated regulation of bile acids (SHP, LRH-1, and HNF4a) in 
HHI 498 and HuH-7. Gene expression was normalized to actin and expressed as fold 
relative to HH1498 (control) (n=2). C) HuH-7 cells and D) ZR-75-1 cells were 
transfected with 5 µg p(FXRE)4-TK-luc, 0.5 µg pRL-CMV, and 1.25 µg of 3.1-FXR 
~MpcDNA3.l(+) empty vector. Luciferase activity for treatments is shown relative to 
SO (control) (n=4). 
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* d notes significance compared to control, p :S 0.05; t denotes significance 
eared to respective treatment in transfection with no exogenous FXR, p :S 0.05. 
comp 
f" re 6: Effects of dose response cotreatments of CDCA with TSPO ligands on ~~-Iuciferase reporter activity. HuH-7 cells were transfected with 5 µg p(FXRE)4-
TK-luc and 0.5 µg pRL-CMV and treated for 24h with CDCA, FGIN-1-27, FGIN-1-
43 or PKI 1195 at varying concentrations. CDCA and FGIN-1-27 were cotreated with 
FGIN-1-43 and PKI 1195 at 10 µM and 1 µM concentrations. CDCA was also 
otreated with FGIN-1-27 at 10 µM and 1 µM concentrations. All values (n=4) are ~xpressed as fold relative to DMSO (control) (n=16). CDCA at 10 µMand 100 µM, 
n==8. White and dark grey bars represent cotreatments at 10 µM and 1 µM, 
respectively, with CDCA or FGIN-1-27 held constant at the noted conce~trat~on. * 
denotes significance compared to control, p :S 0.05, represented by solid lme. t 
denotes significance compared to respective constant treatment, represented by dotted 
line, p :S 0.05. 
Figure 7: Expression of BSEP mRNA in response to ligands of FXR and TSPO. 
Human hepatocytes (HH1486 and HH1498) and HuH-7 cells were treated for 24h at a 
final concentration of 10 µM. Total RNA was reverse transcribed and cDNA was 
subjected to actin and BSEP gene-specific amplification with SYBR green PCR. 
BSEP expression was normalized to actin and treatments are relative to DMSO 
(control) in each experiment. In HH1498 and HuH-7, CDCA and FGIN-1-27 were 
cotreated with FGIN-1-43 or PKI 1195. The CDCA and FGIN-1-27 control treatment 
values are represented by dotted lines. * denotes significance compared to control, p :S 
0.05. t denotes significance compared to respective constant treatment, represented by 
dotted line, p :S 0.05, HH1486 (n=3), HH1498 (n=3), and HuH-7 (n=2). 
Figure 8: Expression of SHP mRNA in response to ligands of FXR and TSPO. 
Human hepatocytes (HH1486 and HH1498) and HuH-7 cells were treated for 24h at a 
final concentration of 10 µM. Total RNA was reverse transcribed and cDNA was 
subjected to actin and SHP gene-specific amplification with SYBR green PCR. SHP 
expression was normalized to actin and treatments are relative to DMSO (control) in 
each experiment. In HH1498 and HuH-7, CDCA and FGIN-1-27 were cotreated with 
FGIN-1-43 or PKll 195. The CDCA and FGIN-1-27 control treatment values are 
represented by dotted lines. * denotes significance compared to control, p :S 0.05. t 
denotes significance compared to respective constant treatment, represented by dotted 
line, p :S 0.05, HH1486 (n=3), HH1498 (n=3), and HuH-7 (n=2). 
Figure 9: Expression of CYP7 Al mRNA in human hepatocytes. Human 
hepatocytes (HH1486 and HH1498) were treated for 24h at a final concentration of 10 
µM. Total RNA was reverse transcribed and cDNA was subjected to actin and 
CYP7A1 gene-specific amplification with SYBR green PCR. CYP7A1 expression 
was normalized to actin and treatments are relative to DMSO (control) in each 
experiment. The schematic illustrates the direct repression of CYP7 Al gene 
expression by SHP via indirect FXR ligand activation. * denotes significance 
compared to control, p :s 0.05, (n=3). 
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F. ure 1 O: Crystallized structure of FXR LBD with MF A-1 in the binding pocket 
%BID code 3BEJ). Each _a-helix in the LBD is labeled (1-1.2) and v~ries by color ~or simpler visual representation. The small fragment of SRC-1 is shown m green. 
figure 11: Molecular modeling of CDCA and TSPO ligands in the LBD of FXR. 
Each compound formed various conformations, grouped into clusters, based upon 
orientation of each atom deviating by 2.0 A RMS. On the graphs, each bar represents 
the number of conformations in a cluster with shared mean free energy of binding ± 
SEM. The brackets, labeled a-d, represent the binding energy range for each 
conformation based upon core ring orientation. Within each bracket, the hydrocarbon 
tails vary in position while the rings maintain the same conformation. The lowest 
energy conformers representing the four bracketed conformation types are shown with 
key amino acid residues highlighted: T = Thr288, R = Arg331, Y = Tyr369, and H = 
His447. Dotted black lines represent hydrogen bonds. Each table shows the frequency 
and mean free energy of binding ± SEM for each bracketed conformation. A) CDCA 
fit into two conformations from 600 GA runs forming hydrogen bonds with T288 in 
conformation a and with R331 and H447 in conformation b. B) FGIN-1-27 formed 
four main conformations from 800 GA runs forming hydrogen bonds with T288 in 
conformation a and with Y369 in conformation b. C) FGIN-1-20 fit into three 
conformations from 800 GA runs forming hydrogen bonds with T288 in conformation 
a and H447 in conformation c. D) Four conformations of FGIN-1-51 were formed 
from 800 GA runs. E) FGIN-1-43 found four conformations from 800 GA runs. F) 
Only one conformation resulted for PKl 1195 from 600 GA runs. 
Figure 12: Effects of point mutations of amino acids predicted to interact with 
ligands inside the LBD of FXR. A) Two conformations (a and b) of CDCA and four 
conformations of FGIN-1-27 (a-d) with the lowest free energy of binding in the LBD 
of FXR. Hydrogen bonds to Thr288, Tyr369, His447 and Arg331 are represented by 
dotted black line. Residues that directly interact with the ligands are highlighted in 
yellow. B) ZR-75-1 cells were transfected with 1 µg of p(FXRE)4-TK-luc, 100 ng 
pRL-CMV, and 500 ng of FXR, either wild type (WT) or hFXR mutant and treated for 
24h with a final concentration of 10 µM. * denotes significance compared to control 
for each mutation, p :::; 0.05 . (n=4). t denotes significance compared to respective 
treatment of WT FXR, p:::; 0.05. 
Figure 13: Involvement of FGIN-1-27 in the alternative pathways of bile acid 
synthesis and homeostasis. 1) FGIN-1-27 binding to TSPO facilitates the transport of 
cholesterol into the mitochondria. 2) The alternative pathway of bile acid synthesis 
produces CDCA. 3) CDCA and FGIN-1-27 can both activate FXR to 4) increase 
BSEP gene expression. 
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8. TABLES 
Table 1. GABA-ergic chemical library 
C0l1-POUND GABAer le ACTIVITY NUMB@ 
~£ GABA Endogenous ligand. 0 7 
Bl 
J-Mcthyl-GABA Activator of GA BA aminotransferase. 08 
Bl Irreversible inhibitor o GABA 
Gabaculinc 1ransaminasc. 09 Bl 
trnns-4-Aminucrolonic add GABA agonist. DIO 
84 
cis-4-Aminocrotonic acid GABAc receptor ligand. Oil 
Bl 
4.5.6. 7 _ T errahydroisoxazolo{ 5, 4-C lpyridin- GABAa receptor agonist. 0 12 
86 3-ol 
( 1,2,5,6· T ctmhydropyri din-4. GABAc receptor antagonist. El 
B7 l)merh I hos hinic acid 
B8 
CGP 35348 GABAb antagonist. E2 
CGP46381 GABAb antagonist . E3 
B9 
CGP 52432 GABAb antagonist. E4 BIO 
CGP 54626 HCI GABAb antagonist. ES Bil 
812 CGP55845 
GABAb antagonist. E6 
Cl Saclofen HCI 
Antagonist at GABAb receptors. E7 
Cl SCH 5091 1 
GABAb antagonist. ER 
C3 (midaw k -4-acctic acid HCI Partial GABAc agonist. E9 
C4 Riluzole HCI GABA uptake inhibitor. E ID 
Cl SKF 89976A HCI GABA uptake inhibitor. Ell 




















Propofol GABAa agonist. Fl 
7-(Dimcthylcarbamoyloxy)-6-phcnylpyrrolo 
C7 
_fl, l-Ill.ll .ll_bcnzothia7:£.12.!ne 
C8 
Me1hyl-6,7-dimethoxy-4-ethyl-b-carboline- Bcnzodiazcpine receptor inverse agonis1. F2 FGTN-1-27 3-carbo~ late 
C9 
(:1:.)-4-Amino-3-(5-chloro-2-thicnyl)- GABAb agonist. F3 FGIN-1 -43 
butanoicacid 
CJO (:1:.)-Baclofcn GABAb agonist. F4 GBLD 345 
Cit (-)-Bicuculline mcthobromidc GABAa antagonist. F5 N-[-( 4-Methoxyphcnyl)cthyl]-3-indol.££! o~amide 
Cl2 Guvacine HCI GABA uptake inhibitor. F6 FG 7142 
DI Jsoguvacine HCI GABAagonist. F7 Zopiclone 
Dl Muscimol GABAa receptor agouisr. FS Flumazcnil 
Dl Phaclofcn GABAb reccptor antagonist. F9 3-Hydroxymethyl-b-carbolioe 
04 SK&F 97541 GABAb agonist. FIO PK-11195 
Dl ZAPA H:2S0-1 Agonist at low affinily GABAa receptors. Fil lsoniazid 





GABAa rect..'Plor ligand. 
Antagonist ofGHB. 
GABAa receptor antagonist. 
GABAa antagonist. 
Positive allostcric modula1or of GABAa Cl 
channel. 




GHB receptor ligand. 
GABA nplake inhibitor. 
Bc01:odiazcpinc I GABA.a ligand 
Benzodiazepine inverse agonist. 
Endogenous proconnilsant and anxiogenic 
benzodiaz.£E.!ne rec~or Ii and. 
Bcnzodia.zepine inverse agonist. 
Benzodiazcpinc invL-rsc agonist 
NIA 
Peripheral bcnzodiazepine receptor ligand 
Peripheral bcnzodiazepinc receptor ligand 
Pcriphcral b..::nzodiazcpine receptor ligand 
A high affinily benzodiazepine agonist. 
An inverse agonist al the bcnzodiazcpinc 
rec~or. 
Inverse agooist and anitiogenic agent. 
A non benzodiazcpine BZR agonist. 
Benzodiazepinc :mtagonisr. 
Bcnzodiazcpinc inverse agonisr. 
Peripheral bcnzodiazcpinc n:ccptor ligand 
Negative allosterie modulator of GABAa 
rCC.£1!.IOrs. 
GABA recc:p1or ligand. 
'XR amino acids Table 2. Point mutations of F 
Seguence !5' - 3'~ 
5 286 287 AA Num. 283 284 28 
Codon aat ttt etc att ttg 
AA N F L I L 
att ttg 
I L 
Codon Mutation aat ttt etc 
AA Mutation N F L 
8 329 330 AA Num. 326 327 32 
Codon gaa get atg 
AA E A M 
Codon Mutation gaa get atg 





9 330 331 AA Num. 327 328 32 
Codon get atg ttc 
AA A M F 
Codon Mutation get atg ttc 





6 367 368 AA Num. 364 365 36 
Codon cct atg m 
AA P M F 
Codon Mutation cct atg ttt 





AA Num. 442 443 44 
Codon aca ttc aa 
4 445 446 
t 
AA T F N 
t Codon Mutation aca ttc aa 





ms- 289 290 291 292 293 
acg gaa atg gca ace aat 
T E M A T N 
ctg gaa atg gca ace aat 
L E M A T N 
[TIT 332 333 334 335 336 
cgt tea get gag att ttc 
R s A E I F 
ctt tea get gag att ttc 
L s A E I F 
332 333 334 335 336 337 
tea get gag att ttc aat 
s A E I F N 
ttt get gag att ttc aat 
F A E I F N 
~ 370 37 1 372 373 374 
tat aaa agt att ggg gaa 
y K s I G E 
ctt aaa agt att ggg gaa 
L K s I G E 
rm 448 449 450 451 452 
cac get gag atg ctg atg 
H A E M L M 
ttc get gag atg ctg atg 







Table 3. Forward and reverse oglionucleotide primer sequences for DNA 
amplification via SYER Green RT-PCR 
5'-3' Sequence 
Actin F - GTTGTCGACGACGAGCG 
R-GCACAGAGCCTCGCCTT 
BSEP F - CATTTCGCTCTCGATGTTCA 
R-TTCCAGGAAAAGCATGTGTG 
CYP7Al F- GGTGCAAAGTGAAATCCTCC 
R-CAGAACTGAATGACCTGCCA 
FXR F - CACAGCGTTTTTGGTAATGC 
R-TTGTTTGTGGAGACAGAGCCT 
HNF4 F - GGCTGCTGTCCTCATAGCTT 
R-GCAGGCTCAAGAAATGCTTC 
LRH-1 F- CGGTAAATGTGGTCGAGGAT 
R-CGAGTGGGCCAGGAGTAGTA 
RXRa F - TGTCAATCAGGCAGTCCTTG 
R-GGGTGTACAGCTGCGAGGG 
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Figure 11 A and B 
A 
CDCA 
a COCA Binding Energy % 
(kcal/mo!) frequency 
a -9 .7539 ± 0 .0086 86.80 
b -9.4465 ± 0 .0279 13.20 
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->R c Y R d Y R FGIN-1-27 Bin ing Energy % 
Y~T y:J<_ T YJiT (kcal/mo!) frequency a -9.3351 ± 0.0272 41.07 b -9.1217 ± 0 .0547 20.45 c -8.7669 ± 0.0512 20.13 
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Figure 11 C and D 
c 
FGIN-1-20 
gJ / R _QJ ~R _ci _J R FGIN-1-20 
B1naing Energy % 
yATY~T Y~T (kca l/mol) frequency a -8.7135 ± 0.0078 59.55 b -8.9750 ± 0.0277 6.74 c -9.1083 ± 0.0160 33.71 
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Bin ing Energy % 
(kcal/mol) frequency 
a -7.3401 ± 0.1579 15.83 
b -8.1590 ± 0.2076 15.13 
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d -8.7693 ± 0.1026 28.70 






... 40 0 
... 30 .. 
,Q 
8 20 












Binding Energy (kcal/mot) 
PK11195 
Binding Energy % 
(kcal/mol) frequency 
-9.6416 ± 0 .0054 100.00 
~ 600 .,.-------------------------------------------------------------
= 0 -~ 500 
8 
.E 400 























FGIN-1-27 a FGIN-1-27 b FGIN-1-27 c FGIN-1-27 d 
Figure 13 













/ .___ _ _ 
BSEP 
